es rappelt im Karton bongggggggg ::::: 3.041.388 shares Nasdaq rt
Gruss B.
Gruss B.
Anzeige
Meldung des Tages: Schon +250 % im Plus – warum diese Goldstory gerade erst startet!!
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
1 2 3 4 6 7 8 9 ...
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter 1 2 3 4 6 7 8 9 ...
Citigroup - Mylan "buy"
Beiträge:
463
Zugriffe: 92.028 / Heute: 12
Zugriffe: 92.028 / Heute: 12
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +77,39%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +58,77%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +58,64%
Xtrackers ATX UCITS ETF 1C
Perf. 12M: +51,64%
Xtrackers Vietnam Swap UCITS ETF 1C
Perf. 12M: +50,29%
Gute Arbeit geleistet aber mit Bravour mal wieder auf's Parkett eine Shanearbeit habt Ihr hingelegt.Buran ist stolz auf Euch.Und Mylan wird weiter gepusht so wie eh und jeh.Sehr schön mit an zu sein und dabei zu sein.Danke.
und noch einen Dankeslink
http://www.ariva.de/news/...n-Relating-to-its-Generic-Silenor-4180231
und noch einen Dankeslink
http://www.ariva.de/news/...n-Relating-to-its-Generic-Silenor-4180231
committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.comhttp://www.ariva.de/news/...n-Relating-to-its-Generic-Silenor-4180231
Tradegate 500 18,36 €
§18,60 € 500 1,31% 13:20:57
Stuttgart 1.090 18,36 €
§18,58 € 1.000 1,20% 13:01:52
Berlin 500 18,37 €
§18,61 € 500 1,31% 13:00:37
Frankfurt 1.091 18,346 €
§18,614 € 1.075 1,46% 13:06:43
Düsseldorf 0 18,345 €
§18,615 € 0 1,47% 13:02:42
München 200 18,345 €
§18,615 € 200 1,47% 13:02:39
Nasdaq 600 22,43 $
§24,00 $ 400 7,00% 10:02:01
§18,60 € 500 1,31% 13:20:57
Stuttgart 1.090 18,36 €
§18,58 € 1.000 1,20% 13:01:52
Berlin 500 18,37 €
§18,61 € 500 1,31% 13:00:37
Frankfurt 1.091 18,346 €
§18,614 € 1.075 1,46% 13:06:43
Düsseldorf 0 18,345 €
§18,615 € 0 1,47% 13:02:42
München 200 18,345 €
§18,615 € 200 1,47% 13:02:39
Nasdaq 600 22,43 $
§24,00 $ 400 7,00% 10:02:01
kleiner Anhang der natürlich nicht fehlen sollte: Aktienanzahl 426,7 Mio.,Gruss Buran
Mylan-Aktie: "overweight"
09:26 25.07.12
London (www.aktiencheck.de) - Douglas D. Tsao und Ann Trimble, Analysten von Barclays Capital, stufen die Aktie von Mylan (Mylan Aktie) weiterhin mit dem Rating "overweight" ein. Das Kursziel werde unverändert bei 26 USD gesehen. (Analyse vom 24.07.2012) (25.07.2012/ac/a/a)
Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.
Quelle: Aktiencheck
09:26 25.07.12
London (www.aktiencheck.de) - Douglas D. Tsao und Ann Trimble, Analysten von Barclays Capital, stufen die Aktie von Mylan (Mylan Aktie) weiterhin mit dem Rating "overweight" ein. Das Kursziel werde unverändert bei 26 USD gesehen. (Analyse vom 24.07.2012) (25.07.2012/ac/a/a)
Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.
Quelle: Aktiencheck
bietet derzeit +2,27% RT an,und die Reise geht weiter lustig und gar heiter :-)
immer wieder nur schön und schön hübsch anzusehen
http://www.ariva.de/news/...k-s-First-Allergy-Awareness-Night-4200052
http://www.ariva.de/news/...k-s-First-Allergy-Awareness-Night-4200052
der enorme Druck welcher jetzt bei Mylan herrscht
folgend die letzten 4 Handelstage,sehr gut zuerkennen
wie ein Vulkan der bläht und kurz vor dem Ausbruch steht
31.07.12 23,34 23,43§23,00 23,03 $ 4.943.739 113 M
30.07.12 23,20 23,42§23,15 23,34 $ 4.707.511 109 M
27.07.12 22,97 23,40§22,93 23,265 $ 9.562.612 222 M
26.07.12 22,45 23,00§22,16 22,75 $ 10.765.108 232 M
folgend die letzten 4 Handelstage,sehr gut zuerkennen
wie ein Vulkan der bläht und kurz vor dem Ausbruch steht
31.07.12 23,34 23,43§23,00 23,03 $ 4.943.739 113 M
30.07.12 23,20 23,42§23,15 23,34 $ 4.707.511 109 M
27.07.12 22,97 23,40§22,93 23,265 $ 9.562.612 222 M
26.07.12 22,45 23,00§22,16 22,75 $ 10.765.108 232 M
könnte man sich das Texten bei Mylan sparen, also das Pushen - geht ganz von Zauberhand allein
http://www.ariva.de/news/...ion-ARVs-Containing-Emtricitabine-4204580
http://www.ariva.de/news/...ion-ARVs-Containing-Emtricitabine-4204580
über die Dreiundzwanziger Marke gedonnert #111 normalerweise was ist denn schon normal - das Begehren ist doch wichtig - nicht einfach links liegen lassen denn dann bekäme man eventuell Komplexe,Geld verdienen ohne etwas dafür zu tun ziert sich doch nicht ;-)
http://www.ariva.de/news/...to-Generic-Drugs-Over-Past-Decade-4204878 news
http://www.ariva.de/news/...to-Generic-Drugs-Over-Past-Decade-4204878 news
realtime: +1,93% bin gespannt auf's kommende update *freu*....Taxe 3-4%
Düsseldorf 19,20 € +0,89%
§19,03 € 0 0 19,20 - 19,20 08:06:24
München 19,19 € +0,49%
§19,095 € 0 0 19,19 - 19,19 08:04:25
Stuttgart 19,20 € G +0,86%
§19,035 € 0 0 19,20 - 19,20 08:01:45
Berlin 19,20 € +0,89%
§19,03 € 0 0 19,20 - 19,20 08:08:37
_______________________________________
Frankfurt und Tradegate leider nichts anzubieten,aber die Nasdaq wird offen werden/Gruss buran
§19,03 € 0 0 19,20 - 19,20 08:06:24
München 19,19 € +0,49%
§19,095 € 0 0 19,19 - 19,19 08:04:25
Stuttgart 19,20 € G +0,86%
§19,035 € 0 0 19,20 - 19,20 08:01:45
Berlin 19,20 € +0,89%
§19,03 € 0 0 19,20 - 19,20 08:08:37
_______________________________________
Frankfurt und Tradegate leider nichts anzubieten,aber die Nasdaq wird offen werden/Gruss buran
besser "brauch" man nix mehr drüber zu sagen.....bedient Euch,Gruss buran
ich auch optimistisch ..!
Mylan - Das große Bild ist bullisch
von André Rain
Freitag 31.08.2012, 21:33 Uhr Download -
+ Mylan Inc. - Kürzel: MYL - ISIN: US6285301072
Börse: Nasdaq in USD / Kursstand: 23,60 $
www.godmode-trader.de/nachricht/...t-bullisch,a2911753,b2.html
Mylan - Das große Bild ist bullisch
von André Rain
Freitag 31.08.2012, 21:33 Uhr Download -
+ Mylan Inc. - Kürzel: MYL - ISIN: US6285301072
Börse: Nasdaq in USD / Kursstand: 23,60 $
www.godmode-trader.de/nachricht/...t-bullisch,a2911753,b2.html
Mylan Selected as a Leading ARV Supplier to India's National AIDS Control Organization
13:35 04.09.12
PR Newswire
HYDERABAD, India and PITTSBURGH, Sept. 4, 2012
HYDERABAD, India and PITTSBURGH, Sept. 4, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Laboratories Limited has been selected as a leading supplier of antiretroviral (ARV) drugs to India's National AIDS Control Organization (NACO). NACO is a division of India's Ministry of Health and Family Welfare and is responsible for overseeing HIV/AIDS control programs in India. NACO's objective is to halt and reverse the HIV/AIDS epidemic in India over the next five years through integrated programs for prevention, care and support and treatment. NACO manages 35 HIV Prevention and Control Societies, which implement NACO's programs at the State level and manage more than 350 ARV treatment centers.
Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's 7 billion people access to high quality medicines, and helping to ensure access to high quality, affordable ARVs is a core part of this mission. Only through access to these vital medicines can we stem the tide of HIV/AIDS in India and around the world. We are honored that Mylan has been selected as a significant supplier to NACO and look forward to helping this critical organization achieve its mission."
Approximately one-third of HIV/AIDS patients in developing countries depend on a Mylan ARV product, and Mylan has recently entered the Indian commercial market, starting with a portfolio of ARV drugs. Mylan's wide range of ARV products includes active pharmaceutical ingredients and 43 first- and second-line finished doses, nine of which are pediatric products.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
Quelle: PR Newswire
13:35 04.09.12
PR Newswire
HYDERABAD, India and PITTSBURGH, Sept. 4, 2012
HYDERABAD, India and PITTSBURGH, Sept. 4, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Laboratories Limited has been selected as a leading supplier of antiretroviral (ARV) drugs to India's National AIDS Control Organization (NACO). NACO is a division of India's Ministry of Health and Family Welfare and is responsible for overseeing HIV/AIDS control programs in India. NACO's objective is to halt and reverse the HIV/AIDS epidemic in India over the next five years through integrated programs for prevention, care and support and treatment. NACO manages 35 HIV Prevention and Control Societies, which implement NACO's programs at the State level and manage more than 350 ARV treatment centers.
Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's 7 billion people access to high quality medicines, and helping to ensure access to high quality, affordable ARVs is a core part of this mission. Only through access to these vital medicines can we stem the tide of HIV/AIDS in India and around the world. We are honored that Mylan has been selected as a significant supplier to NACO and look forward to helping this critical organization achieve its mission."
Approximately one-third of HIV/AIDS patients in developing countries depend on a Mylan ARV product, and Mylan has recently entered the Indian commercial market, starting with a portfolio of ARV drugs. Mylan's wide range of ARV products includes active pharmaceutical ingredients and 43 first- and second-line finished doses, nine of which are pediatric products.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
Quelle: PR Newswire
und gerade news rein,Vorsicht heiss und fettig ;-)
http://www.ariva.de/news/...Its-Generic-Brand-Reference-Guide-4248977
http://www.ariva.de/news/...Its-Generic-Brand-Reference-Guide-4248977
eine MYLAN kann das nicht,sieh in meine AUGEN und dann sieh in mein BERICHT:::
Canaccord Genuity - Mylan-Aktie: "hold"
11:12 11.09.12
Vancouver (www.aktiencheck.de) - Randall Stanicky und Dana Flanders, Analysten von Canaccord Genuity, bewerten die Mylan-Aktie (Mylan Aktie) mit dem Votum "hold". Das Kursziel werde bei 25,00 USD gesehen. (Analyse vom 10.09.2012) (11.09.2012/ac/a/a)
Offenlegung von möglichen Interessenskonflikten: Das Wertpapierdienstleistungsunternehmen oder ein mit ihm verbundenes Unternehmen betreuen die analysierte Gesellschaft am Markt. Weitere mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.
Quelle: Aktienchec
Canaccord Genuity - Mylan-Aktie: "hold"
11:12 11.09.12
Vancouver (www.aktiencheck.de) - Randall Stanicky und Dana Flanders, Analysten von Canaccord Genuity, bewerten die Mylan-Aktie (Mylan Aktie) mit dem Votum "hold". Das Kursziel werde bei 25,00 USD gesehen. (Analyse vom 10.09.2012) (11.09.2012/ac/a/a)
Offenlegung von möglichen Interessenskonflikten: Das Wertpapierdienstleistungsunternehmen oder ein mit ihm verbundenes Unternehmen betreuen die analysierte Gesellschaft am Markt. Weitere mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.
Quelle: Aktienchec
das ist für mich Balsam für Seele und Depot,jeder hat so seine Macken hier ;-)
. ..rt+0,31%
. ..rt+0,31%
Aktie & Unternehmen
BranchePharmazie
Herkunft USA§
Indizes/Listen§NASDAQ 100, S&P 500
Aktienanzahl§426,7 Mio. (Stand: 31.12.11)
Marktkap.§10.245 Mio. $
Gruss buran
BranchePharmazie
Herkunft USA§
Indizes/Listen§NASDAQ 100, S&P 500
Aktienanzahl§426,7 Mio. (Stand: 31.12.11)
Marktkap.§10.245 Mio. $
Gruss buran
Mylan Launches Generic Version of Antivert® Tablets, 12.5 mg, 25 mg and 50 mg
13:35 21.09.12
PR Newswire
PITTSBURGH, Sept. 21, 2012
PITTSBURGH, Sept. 21, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Meclizine Hydrochloride Tablets USP, 12.5 mg, 25 mg and 50 mg. This product is the generic version of Pfizer's Antivert®, which is indicated for the management of nausea and vomiting, and dizziness associated with motion sickness.
Antivert® Tablets, 12.5 mg, 25 mg and 50 mg, had U.S. sales of approximately $53.5 million for the 12 months ending June 30, 2012, according to IMS Health. Mylan is shipping this product immediately.
Currently, Mylan has 169 ANDAs pending FDA approval representing $79.4 billion in annual sales, according to IMS Health. Thirty-four of these pending ANDAs are potential first-to-file opportunities, representing $22.4 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
Quelle: PR Newswire
13:35 21.09.12
PR Newswire
PITTSBURGH, Sept. 21, 2012
PITTSBURGH, Sept. 21, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Meclizine Hydrochloride Tablets USP, 12.5 mg, 25 mg and 50 mg. This product is the generic version of Pfizer's Antivert®, which is indicated for the management of nausea and vomiting, and dizziness associated with motion sickness.
Antivert® Tablets, 12.5 mg, 25 mg and 50 mg, had U.S. sales of approximately $53.5 million for the 12 months ending June 30, 2012, according to IMS Health. Mylan is shipping this product immediately.
Currently, Mylan has 169 ANDAs pending FDA approval representing $79.4 billion in annual sales, according to IMS Health. Thirty-four of these pending ANDAs are potential first-to-file opportunities, representing $22.4 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
Quelle: PR Newswire
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Mylan Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
5 | 462 | Citigroup - Mylan "buy" | buran | buran | 25.04.21 01:35 | |
| 2 | Pfizer und Mylan erwägen Fusion bei patentfreiem A | JKHA | 29.07.19 10:02 |